Stifel analyst Rick Wise lowered the firm’s price target on OrthoPediatrics (KIDS) to $20 from $32 and keeps a Buy rating on the shares after the company pre-announced below-consensus Q3 sales and lowered 2025 guidance by more than the shortfall. The negative Q3 surprise “clearly is disappointing,” but the factors driving the miss appear to be outside of managements’ control, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics price target lowered to $22 from $30 at Piper Sandler
- OrthoPediatrics: Strong Growth Prospects and Acquisition Potential Justify Buy Rating
- Closing Bell Movers: Levi Strauss down 8% after results
- OrthoPediatrics reports preliminary Q3 revenue $61.2M, consensus $63.63M
- OrthoPediatrics cuts FY25 revenue view to $233.5M-$234.5M from $237M-$242M